Name: Calliditas Therapeutics AB (CALT) Stock
Brand: Calliditas Therapeutics AB
Rating: 6.5 (3 reviews)

CALT Latest News, Press Relases and Analysis

All

Press Releases

a year ago - By: Investor's Business Daily - Mentions: TVTX

Travere Stock Pops After Snagging Full Approval For Calliditas Rival In Kidney Disease

a year ago - By: Calliditas Therapeutics

Calliditas Therapeutics takes certain corporate actions following announcement by Asahi Kasei

a year ago - By: InvestorPlace

CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Beats Revenue for Q2 2024

a year ago - By: Calliditas Therapeutics

Calliditas Interim Report January to June 2024

a year ago - By: Halper Sadeh LLC - Mentions: BALY MRO SHCR

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BALY, MRO, SHCR, CALT on Behalf of Shareholders

a year ago - By: Calliditas Therapeutics

Calliditas announces positive TRANSFORM Phase 2b topline data in primary biliary cholangitis

a year ago - By: Calliditas Therapeutics

Launch of Phase 3 clinical trial with Nefecon in Japan

a year ago - By: Calliditas Therapeutics

Calliditas provides setanaxib patent update

a year ago - By: Calliditas Therapeutics

Calliditas partner STADA receives European Commission decision for full approval of Kinpeygo® for the treatment of IgA Nephropathy

2 years ago - By: Benzinga

Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know

2 years ago - By: Calliditas Therapeutics

Calliditas partner STADA receives positive CHMP opinion recommending full approval for Kinpeygo® for the treatment of IgA nephropathy

2 years ago - By: Calliditas Therapeutics

Calliditas Therapeutics Presents Data at the 61st European Renal Association Congress

2 years ago - By: Calliditas Therapeutics

In-Person & Virtual R&D Day: The Anti-Fibrotic Effects of Setanaxib and TARPEYO's Mode of Action

2 years ago - By: Calliditas Therapeutics

Calliditas Therapeutics to Present Data at ERA 2024 May 23 - 26 in Stockholm

2 years ago - By: Benzinga - Mentions: ESLT INSM APDN NCPL ...

Crude Oil Rises Sharply; Elbit Systems Shares Fall After Q1 Results

2 years ago - By: Calliditas Therapeutics

Calliditas' Partner Everest Medicines Starts Commercial Launch of Nefecon in China

2 years ago - By: Calliditas Therapeutics

Calliditas Therapeutics' 2023 Annual Report Published

2 years ago - By: Calliditas Therapeutics

Calliditas Announces Positive NefIgArd Open Label Extension Results

2 years ago - By: Halper Sadeh LLC

CALT STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Calliditas Therapeutics AB Is Fair to Shareholders

2 years ago - By: InvestorPlace - Mentions: STSS INSM TKLF OBLG ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

2 years ago - By: Calliditas Therapeutics

Statement by the Board of Directors of Calliditas Therapeutics AB (publ) in relation to the public offer by Asahi Kasei Corporation

2 years ago - By: InvestorPlace

CALT Stock Earnings: Calliditas Therapeutics Misses EPS, Misses Revenue for Q1 2024

2 years ago - By: Calliditas Therapeutics

Calliditas announces positive topline results of Phase 2 head and neck cancer trial with lead NOX inhibitor candidate, setanaxib

2 years ago - By: Calliditas Therapeutics

Calliditas Therapeutics Presents Additional Data Analyses from the Phase 3 NeflgArd trial of Nefecon in Primary IgA Nephropathy at the ISN World Congress of Nephrology 2024

Calliditas Therapeutics AB (CALT) Stock News

CALT Latest News, Press Relases and Analysis